Efficacy in Multiple Myeloma
In 2 multicenter, randomized, double-blind, placebo-controlled Phase III studies comparing REVLIMID® + oral pulse dexamethasone to placebo + dex in patients who had received at least 1 prior treatment, REVLIMID® + dex significantly extended time to progression.
- Results of pooled analysis from Studies 1 and 2 showed that REVLIMID® + dex doubled median time to progression (9.3 months compared with 4.6 months for placebo + dex).
- More than 50% of patients achieved a response with REVLIMID® + dex.
- Consistent results were observed in North American and international Phase III studies.
- Time to progression curves for the 2 treatment arms separated early and remained separate throughout the study period.
*Based on preplanned interim analysis. As of July 15, 2004 (Study 1) and September 15, 2004 (Study 2).
Time to progression was calculated as the time from randomization to the first occurrence of either of the following events:
- Disease progression based on the myeloma response criteria developed by Bladé et al
- Discontinuation from the treatment phase due to disease progression according to the investigator, whether or not confirmed by the Bladé et al criteria (TTP was measured to the last date of visit), or death due to disease progression during the treatment period (TTP was measured to the date of death if death occurred on or before treatment discontinuation)
*Based on preplanned interim analysis. As of July 15, 2004 (Study 1) and September 15, 2004 (Study 2).
Results of 2 randomized, double-blind, placebo-controlled studies comparing REVLIMID® + dex to placebo + dex in patients who had received at least 1 prior treatment.
Overall response (OR) = CR + PR (EBMT/IBMTR/ABMTR criteria†)
Complete response (CR): complete (100%) disappearance of myeloma protein and negative immunofixation electrophoresis (no trace amounts of M-protein); <5% plasma cells in bone marrow; stable disease via skeletal x-ray; and disappearance of soft tissue plasmacytomas.
Partial response (PR): >50% disappearance of myeloma protein; stable disease via skeletal x-ray; and, when present, at least 50% reduction in the sum of the products of perpendicular diameters of measurable soft tissue plasmacytomas compared to baseline (as assessed by radiography or clinical examination); and no evidence of progression.
†Includes 2 assessments performed 6 weeks apart. Responses must have lasted at least 6 weeks.
Learn about the safety profile of REVLIMID® + dex.
|
REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
|
|
REVLIMID® (lenalidomide) is indicated for patients with transfusion-dependent anemia due to Low- or Intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
|
Important Safety Information
|
WARNINGS:
1. POTENTIAL FOR HUMAN BIRTH DEFECTS.
Lenalidomide is an analogue of thalidomide. Thalidomide is a known human teratogen
that causes severe life-threatening human birth defects. If lenalidomide is taken
during pregnancy, it may cause birth defects or death to an unborn baby. Females
should be advised to avoid pregnancy while taking REVLIMID®
(lenalidomide).
|
|
Special Prescribing Requirements
|
Because of this potential toxicity and to avoid fetal
exposure to REVLIMID® (lenalidomide),
REVLIMID® (lenalidomide) is only
available under a special restricted distribution program. This program is called
“RevAssist®”. Under this program,
only prescribers and pharmacists registered with the program can prescribe and dispense
the product. In addition, REVLIMID®
(lenalidomide) must only be dispensed to patients who are registered and meet all
the conditions of the RevAssist® program.
2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA).
This drug is associated with significant neutropenia and thrombocytopenia. Eighty
percent of patients with del 5q myelodysplastic syndromes had to have a dose delay/reduction
during the major study. Thirty-four percent of patients had to have a second dose
delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled
in the study. Patients on therapy for del 5q myelodysplastic syndromes should have
their complete blood counts monitored weekly for the first 8 weeks of therapy and
at least monthly thereafter. Patients may require dose interruption and/or reduction.
Patients may require use of blood product support and/or growth factors. (see DOSAGE
and ADMINISTRATION)
3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM.
This drug has demonstrated a significantly increased risk of deep venous thrombosis
(DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated
with REVLIMID® (lenalidomide)
combination therapy. Patients and physicians are advised to be observant for the
signs and symptoms of thromboembolism. Patients should be instructed to seek medical
care if they develop symptoms such as shortness of breath, chest pain, or arm or
leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet
therapy prescribed in conjunction with REVLIMID®
(lenalidomide) may lessen the potential for venous thromboembolic events. The decision
to take prophylactic measures should be done carefully after an assessment of an
individual patient’s underlying risk factors.
You can get the information about REVLIMID®
(lenalidomide) and the RevAssist®
program on the Internet at www.REVLIMID.com or by calling the manufacturer's
toll-free number at
1-888-423-5436.
|
|
ADDITIONAL WARNINGS: HEMATOLOGIC TOXICITY
Multiple Myeloma
- In the pooled multiple myeloma studies, Grade 3 and 4 hematologic toxicities were more frequent in patients treated with the combination of REVLIMID® (lenalidomide) and dexamethasone than in patients treated with dexamethasone alone
- Patients on therapy should have their complete blood counts monitored every 2 weeks for the first 12 weeks and then monthly thereafter
- Patients may require dose interruption and/or dose reduction
CONTRAINDICATIONS:
Hypersensitivity:
- REVLIMID®(lenalidomide) is contraindicated in any patients who have demonstrated hypersensitivity to the drug or its components
PRECAUTIONS:
Renal impairment:
- Since lenalidomide is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID® (lenalidomide) are recommended to provide appropriate drug exposure in patients with moderate or severe (CLcr < 60 mL/min) renal impairment and in patients on dialysis
- Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it would be prudent to monitor renal function
Nursing mothers:
- It is not known whether REVLIMID® (lenalidomide) is excreted in human milk
- Because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother
ADVERSE REACTIONS:
Multiple Myeloma
- In the REVLIMID® (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID® (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group
- Of these patients who had one dose interruption with or without a dose reduction, 50% in the REVLIMID® (lenalidomide)/dexamethasone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group
- Most adverse events and Grade 3/4 adverse events were more frequent in MM patients who received the combination of REVLIMID® (lenalidomide)/dexamethasone compared to placebo/dexamethasone
Other adverse events reported in multiple myeloma patients (REVLIMID® (lenalidomide)/dexamethasone vs dexamethasone/placebo): constipation (39% vs 19%), fatigue (38% vs 37%), insomnia (32% vs 37%), muscle cramp (30% vs 21%), diarrhea (29% vs 25%), neutropenia (28% vs 5%), anemia (24% vs 17%), asthenia (23% vs 25%), pyrexia (23% vs 19%), nausea (22% vs 19%), headache (21% vs 21%), peripheral edema (21% vs 19%), dizziness (21% vs 15%), dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%).
Myelodysplastic Syndromes
- Thrombocytopenia (61.5%; 91/148) and neutropenia (58.8%; 87/148) were the most frequently reported adverse events observed in the del 5q MDS population
Other adverse reactions reported in del 5q MDS patients (REVLIMID® (lenalidomide)): diarrhea (49%), pruritus (42%), rash (36%), fatigue (31%), constipation (24%), nausea (24%), nasopharyngitis (23%), arthralgia (22%), pyrexia (21%), back pain (21%), peripheral edema (20%), cough (20%), dizziness (20%), headache (20%), muscle cramp (18%), dyspnea (17%), and pharyngitis (16%).
DOSAGE AND ADMINISTRATION:
- Dosing is continued or modified based upon clinical and laboratory findings. Dosing modifications are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to REVLIMID® (lenalidomide)
- For other Grade 3 or 4 toxicities judged to be related to REVLIMID® (lenalidomide), hold treatment and restart at next lower dose level when toxicity has resolved to less than or equal to Grade 2
|
Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.
|
|
|
|
